Tag:
Vibativ
Latest Headlines
Latest Headlines
Astellas dumps Theravance's MRSA drug Vibativ
Astellas Pharma parted ways with Theravance ($THRX), ending a promotional partnership on the infection-fighter Vibativ. FDA-approved in 2009, the drug targets infections caused by resistant staph
FDA wants more studies of Vibativ for pneumonia
The FDA wants more data on Theravance's Vibativ (telavancin) before it will approve the treatment for nosocomial pneumonia. The agency suggested a design for any new trials, which means getting the
